Ark Diagnostics has begun commercialisation activities for CE-marked anti-epileptic drug assays in Europe.
The monitoring of anti-epileptic drugs can provide clinicians with data for optimising a patient's medication regimen, especially in situations with complicating physiological or pharmacological factors.
Ark Diagnostics has developed proprietary homogeneous enzyme immunoassays for Lamotrigine, Levetiracetam, Zonisamide, Topiramate and Gabapentin.
All are liquid-stable, ready-to-use reagents that can be adapted for use on a range of clinical chemistry systems.
These tests are typically performed on HPLC systems, however with the advent of the Ark products, these tests can now join the routine laboratory repertoire, therefore enabling rapid result turnaround and improved patient monitoring.
Ark Diagnostics has partnered with KKPD, a Munich-based organisation specialised in supporting companies to develop their European market position.
The aim is to focus upon key laboratories across Europe and rapidly establish a customer base.
